Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.70 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676467 | 0.83 | GABRA1 (0.44) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL62557 | 0.83 | GABRA1 (1.00) | GABRA1GABRB2TSHRMAPT | |
| SCHEMBL7886411 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL30844600 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL3671514 | 0.78 | LIPG (0.44) | GABRA1GABRB2PARP1TLR8 | |
| SCHEMBL25084418 | 0.78 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL39547 | 0.78 | — | — | |
| SCHEMBL29565534 | 0.78 | — | — | |
| SCHEMBL5929950 | 0.77 | ALDH1A1 (0.40) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL31035446 | 0.77 | ALDH1A1 (0.40) | GABRA1GABRB2CYP3A4TSHRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-9365566-B2 | Cinnoline derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038510-A1 | CINNOLINE DERIVATIVES | TAKEDA CALIFORNIA, INC. | 2015-02-05 | — | — | US | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013148603-A1 | CINNOLINE DERIVATIVES AS AS BTK INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-03 | — | — | WO | disclosed |
| US-6774132-B1 | Spirooxindole derivatives that act as analgesics | ASTRAZENECA AB (SE) | 2004-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038510-A1 | CINNOLINE DERIVATIVES | BTK, LYN, ABL1 | GABRA1 2900/4885GABRB2 3283/4885CYP3A4 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.